Objective: Several randomized control trials (RCTs) have compared somatostatin and its analogues versus a control group in patients with enterocutaneous fistulas (ECF). This study meta-analyzes the literature and establishes whether it shows a beneficial effect on ECF closure. Methods: We searched MEDLINE, EMBASE, CINAHL, Cochrane, and PubMed databases according to PRISMA guidelines. Seventy-nine articles were screened. Nine RCTs met the inclusion criteria. Statistical analyses were performed using Review Manager 5.1.
and cholecystokinin, which in turn reduce gastric and pancreatic secretions. In addition, somatostatin reduces splanchnic blood flow, reduces the rate of gastric emptying, and inhibits gallbladder contraction. As a result of the short half-life, a number of synthetic analogues have been developed, and of these, octreotide is used most commonly in the treatment of gastrointestinal fistula. 4 Its significantly longer half-life allows it to be given by intermittent subcutaneous injection (usually 3 times daily). Despite the similarities, the receptor binding properties of somatostatin and octreotide are not identical and their actions may not be equivalent. 4 Enterocutaneous fistulas (ECF) are abnormal communications between the gastrointestinal tract and the skin. Although rare, they are associated with considerable morbidity and mortality. Death related to ECF remains disproportionately high when compared with other surgical conditions. Mortality rates for ECF have been reported to range from 6% to 33%. [4] [5] [6] [7] [8] Fistula formation can result in a number of serious or debilitating complications, varying from disturbance of fluid and electrolyte balance to sepsis and even death. The patient will almost always suffer from severe discomfort and pain. They may also have psychological problems, which include anxiety over the course of their disease, and a poor body image due to the malodorous drainage fluid. 9 Postoperative fistula formation often results in prolonged hospitalization, patient disability, and enormous cost.
Both somatostatin and octreotide have been described as effective treatments for ECF in adults, with few short-term side effects (diarrhea, flushing, and abdominal pain). Accelerating spontaneous ECF closure reduces the period of parenteral nutrition requirement and the morbidity inherent to long-lasting conservative treatment. There is also the potential benefit of reducing patient's discomfort, shortening the length of hospital stay and of cutting the cost of ECF treatment. Some authors argue that high cost, equivocal therapeutic effect on underlying diseases, painful injections, and the potential for long-term side-effects make the use of somatostatin and its analogues controversial. 3 Although there are data suggesting reduced time to fistula closure, there is little evidence of increased probability of spontaneous closure. 4 There have been several randomized control trials (RCTs) and studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] comparing somatostatin and somatostatin analogues versus standard medical therapy or a placebo (control group) in patients with ECF. The objective of this study is to undertake a meta-analysis of the published literature to assess the efficacy of somatostatin and somatostatin analogues in the treatment of ECF.
METHODS
medical subject headings "enterocutaneous" and "fistula." Irrelevant articles and reviews evident from the titles and abstracts were excluded. Relevant articles referenced in these publications were obtained and the "related article" function was used to widen the results. No language restriction was applied and trials on patients of any age or sex were included. All abstracts, comparative studies, non-RCTs, and citations were searched comprehensively. A flow chart of the literature search according to PRISMA guidelines 21 is shown in Figure 1 . Seventy-nine articles were screened for relevance. On further scrutiny, 9 RCTs were found to have useful data for this meta-analysis.
Each article was critically reviewed by 2 researchers using a double extraction method for eligibility in our review. This was performed independently, and conflicts, if any, were resolved before final analysis. A third researcher confirmed the data extraction. Outcome measures were chosen on the basis of whether they were common to the included articles.
Statistical analyses were performed using Review Manager 5.1 (RevMan; Cochrane Collaboration, Copenhagen, Denmark). 22 A value of P < 0.05 was chosen as the significance level for outcome measures. For continuous data (time to closure of fistula), the Inverse-Variance method was used for the combination of standardized mean differences. Binary data (number of fistula closed and mortality) were summarized as risk ratios (RRs) and combined using the Mantel-Haenszel method. In each case, a heterogeneity test was carried out to see whether the fixed effects model was appropriate.
In a sensitivity analysis, 1 was added to each cell frequency for trials in which no event occurred, according to the method recommended by Deeks et al. 23 Where standard deviations were not reported, these were estimated from either ranges or P values. Forest plots were used for the graphical display.
RESULTS
Thirteen full-text articles were retrieved from the electronic databases and assessed for eligibility. Four trials 10, 15, 18, 24 were excluded and their reasons are explained in Table 1 . Nine RCTs comparing somatostatin and somatostatin analogues for use in the management of ECF were included in our study according to our criteria.
Characteristics of trials comparing somatostatin analogues (octreotide and lanreotide) with the control or placebo are given in Table 2 . Characteristics of trials comparing somatostatin with the control or placebo are given in Table 3 . Leondros et al 14 compared 3 groups in the study-somatostatin, octreotide, and control. Characteristics and outcomes of this study were separated into both of the relevant tables accordingly. There were 141 patients in the somatostatin analogue group and 147 in the control or placebo group. When comparing somatostatin with the control or placebo, there were 82 and 85 patients in each group, respectively. The outcome variables extracted are shown in Tables 4 and  5 . The methodological quality of the included trials is explained comprehensively in Tables 6 25,26 and 7. 18 Series of 27 patients treated with octreotide after having received parenteral nutrition for a mean of 25 days. Non-RCT. Kusuhara et al 24 Reduction of the effluent volume in high-output ileostomy patients by a somatostatin analogue octreotide. Not related to ECF. Nubiola-Calonge et al 15 Blind evaluation crossover trial. Patients randomized to 2 days of octreotide followed by 2 days on placebo or vice versa, after which all patients were treated with octreotide. Inadequate length of study arms before randomization. 
Somatostatin Analogues Versus Control Number of Fistula Closed
Six studies 9, 11, 13, 14, 16, 17 contributed to a summative outcome. There was no significant heterogeneity among trials (Q = 9.38, df = 5 (P = 0.09); I 2 = 47%). The number of ECF closed was significantly greater in the somatostatin analogue group (n = 100/152) compared with somatostatin analogues (n = 141) compared with the control (n = 147) group [fixed effects model: SMD = −0.51, 95% CI (−0.75, −0.28), z = 4.27, P < 0.0001; Fig. 3 ].
Mortality
Five studies 9,11,13,14,16 reported on mortality. There was no significant heterogeneity among the trials [Q = 1.03, df = 4 (P = 0.90); I 2 = 0%]. No significant difference was highlighted between analogues (n = 17/141) and controls (n = 21/147) [fixed effects model: RR = 0.89, 95% CI (0.50, 1.56), z = 0.41, P = 0.68; Fig. 4 ].
Somatostatin Versus Control Number of Fistula Closed
Four studies 12, 14, 19, 20 contributed to a summative outcome. There was significant heterogeneity among trials [τ 2 = 0.84; Q = 19.07, df = 3 (P = 0.0003); I 2 = 84%]; therefore, the fixed effects model was inappropriate. There was a significant difference with a greater number of ECF closed with the use of somatostatin (n = 61/82) as compared with control group (n = 30/85) [random effects model: RR = 2.79, 95% CI (1.03, 7.56), z = 2.02, P = 0.04; 
Time to Closure
Four trials 12, 14, 19, 20 reported on time to closure. There was no significant heterogeneity among the trials [Q = 1.06, df = 3 (P = 0.79); I 2 = 0%]. There was a significant difference, with ECF more likely to close faster with somatostatin (n = 82) than with controls (n = 85) [fixed effects model: SMD = −0.79, 95% CI (−1.11, −0.47), z = 4.86, P < 0.00001; Fig. 6 ].
Mortality
Four studies 12, 14, 19, 20 reported on mortality. There was no significant heterogeneity among the trials [Q = 0.12, df = 3 (P = 0.99); 
Fistula Output
Of the 9 RCTs, fistula output reduction was not recorded in 3 trials. 11, 12, 14 Torres et al 20 recorded a significant reduction in number of days (P < 0.05 and P < 0.01, respectively) in the somatostatin group when compared with the control group for a 50% or 75% reduction in output volume, respectively. Spiliotis et al 19 records that the somatostatin group had a 50% reduction in fistula volume in 3
Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. days, in comparison with 1 week in the control group. This is commented to be a significant difference. Jamil et al 13 recorded time for fistulous secretions to cease at 7, 14, 21, and 28 days when comparing octreotide to the control group. No significant difference was noted in the reduction of secretions. Sancho et al 16 recorded no significant difference in fistula output at 24, 48, or 72 hours between octreotide and the control group. Scott et al 17 recorded fistula losses during 12 days of placebo and octreotide injections. They noted no advantage in reduction in fistula losses. Gayral et al 9 showed a significant (P = 0.005) mean reduction in fistula output at 72 hours of 45.1% in the lanreotide group versus 8.9% in the control group.
DISCUSSION
Somatostatin receptors comprise a family of 5 heptahelical membrane proteins encoded by 5 related genes that map to separate chromosomes. 28 The clinically used somatostatin analogues, octreotide and lanreotide, act primarily by only binding to somatostatin receptor 2, 29 and this may contribute to a comparatively less effective outcome.
Octreotide has a much longer half-life (approximately 90 minutes, compared with 1-2 minutes for somatostatin). Because it is absorbed poorly from the gut, it is administered parenterally (subcutaneously, intramuscularly, or intravenously). The pharmacokinetic and pharmacodynamic differences between somatostatin and its analogues require continuous infusion with somatostatin and the parenteral route for analogues.
In this meta-analysis, we have evaluated the effect of somatostatin and its analogues as an effective treatment for fistula closure. Somatostatin was shown to be associated with an increased number of fistulas closed and a reduced time to closure when compared with analogues.
All trials comparing somatostatin with the control favored somatostatin. All but one trial, 17 comparing somatostatin analogues with the control, favored somatostatin analogues. In comparing somatostatin analogues with the control, there was a significant difference in only one study 9 for fistula closure. Gayral et al 9 recorded a significant difference (P = 0.006) with the use of the long acting analogue, lanreotide in fistula closure versus the control.
The study by Scott et al 17 was the only trial where the number of fistula closed was better in the control group rather than the somatostatin analogue group. This is highlighted in the Forest Plot Figure 2 . This anomalous result may be explained by the reduced duration of use of octreotide (12 days) when compared with other studies. Most of the studies use octreotide 3 times per day as a subcutaneous injection 11, 13, 14, 16, 17 but a continuous infusion may be more effective as demonstrated in the study using lanreotide (half-life: 2 hours) 9, 30 where a significant increased rate of fistula closure was observed. Further research with continuous infusion of somatostatin analogues may be useful to evaluate this.
Somatostatin analogues are often thought to be effective at a clinical level, as fistula output will often decrease as they are introduced. This study has not been able to analyze the effect on fistula output because of the variation in reporting this between the studies. There was wide variability in the methodology to record fistula output. Pooling of data was not possible, and hence a summative comparison was excluded from the meta-analysis.
It can be noted from the trials where fistula output was recorded that both trials using somatostatin 19, 20 showed a significant benefit in fistula output reduction. However, we are unable to elucidate whether this has an effect on closure rates.
The 3 trials using octreotide 13, 16, 17 showed no significant benefit in fistula output reduction and closure rates. In contrast, the long acting analogue, lanreotide, had both significant benefit in fistula output reduction and number of fistula closed.
Some authors have reported that enteral elemental diets may reduce fistula output as much as parenteral nutrition 4, 31 without the associated complications of central line sepsis, thrombosis, or pneumothorax, and hence adherence to a short bowel regime is the most effective way of decreasing fistula output. This is also relevant when considering the use of somatostatin, as it is believed to induce intestinal atrophy.
Common adverse effects of treatment with somatostatin analogues include nausea, abdominal cramps, loose stools, mild steatorrhea (presumably resulting from transient inhibition of pancreatic exocrine secretion and malabsorption of fat), and flatulence. These symptoms start within hours of the first subcutaneous injection, are dose-dependent, and usually subside spontaneously within the first few weeks of treatment. 32 In particular, there is the risk of developing gallstones in patients undergoing therapy with somatostatin analogues. Rates approaching 50% have been reported when used in treating patients with metastatic gut neuro endocrine tumours or malignant islet cell tumors. 33 Data on complications including catheter, abdominal, urinary sepsis, pneumothorax, pneumonia, wound, or skin problems were limited. Torres et al 20 reported a greater complication rate within the somatostatin study group (68.75%, 11/16 patients) than the control group (35%, 7/20 patients). This was a significant difference. Isenmann et al 12 and Leondros et al 14 noted no significant difference in complications between the study groups. Jamil et al 13 had a 50% less complication rate in the somatostatin group when compared with the control group.
There was a wide variability in population characteristics in all the studies analyzed. Torres et al 20 had a significant difference in the mean ages between the comparison groups and fistula output before the commencement of the trial. Leondros et al 14 showed a significant difference in mean age within the somatostatin group as opposed to the octreotide and control groups. There was wide variability in the location of fistula as well as the criteria used to define low or high output fistula in all studies ( Table 2 ). All studies except 1 17 stated time to closure.
In 5 11, 13, 14, 16, 17 of the 6 RCTs that compared octreotide to standard medical therapy, a dose of 100 μg subcutaneous injection 3 times per day was used, for a range of durations. When comparing somatostatin with the control, 3 of the 4 studies 12,14,19 used a continuous somatostatin intravenous infusion dose of 250 μg per hour, for varying durations. Reviewing "time to closure" for each of these studies, the current literature supports the use of either octreotide 100 μg subcutaneous injection 3 times daily or somatostatin intravenous infusion dose of 250 μg per hour for a minimum period of 2 weeks. The study of Sancho et al 16 was the only trial to comment on when treatment should be commenced in relation to the duration of an ECF. Their inclusion criteria included all patients with postoperative ECF of less than 8 days' duration with a daily output greater than 50 mL.
Our meta-analysis is limited because of several studies having small numbers of patients recruited. There is further limitation due to the wide variability in study designs, which has been reflected in patient characteristics and study protocol. There is also a lack of clear definitions relating to the recording of study outcomes: fistula closure, time of fistula closure, fistula output reduction, complication rate, and mortality. There was no significant heterogeneity except for when comparing somatostatin with the control for the number of fistulas closed. This may relate to the study of Spiliotis et al 19 having a higher number of patients in the control group than any other studies.
CONCLUSIONS
Our meta-analysis suggests that somatostatin and octreotide increase the likelihood of fistula closure. Both are beneficial in reducing the time to fistula closure. Neither has a significant effect on mortality when compared with standard medical treatment. The best results were after the use of somatostatin or long acting somatostatin analogue, lanreotide.
The RR for somatostatin was higher than the RR for analogues. This may suggest that somatostatin is more effective than analogues in relation to the number of fistulas closed and time until closure. Further studies are required comparing these 2 agents to corroborate these findings.
Recommendation is for a large RCT with adequate patient numbers or a multicenter trial with well-defined criteria and agreed parameters between the participating centers. If a clear option is identified, this would benefit an already surgically challenging group of patients associated with a high morbidity and mortality where it is deemed standard medical treatment has failed.
